Hans Petter Eikesdal

1.8k total citations
41 papers, 987 citations indexed

About

Hans Petter Eikesdal is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Hans Petter Eikesdal has authored 41 papers receiving a total of 987 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 16 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in Hans Petter Eikesdal's work include Angiogenesis and VEGF in Cancer (7 papers), BRCA gene mutations in cancer (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Hans Petter Eikesdal is often cited by papers focused on Angiogenesis and VEGF in Cancer (7 papers), BRCA gene mutations in cancer (6 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Hans Petter Eikesdal collaborates with scholars based in Norway, United States and Denmark. Hans Petter Eikesdal's co-authors include Per Eystein Lønning, Raghu Kalluri, Olav Dahl, Helge Wiig, Stian Knappskog, Marek Wagner, Olav Mella, Rolf Bjerkvig, Kari Alitalo and Manuel Fankhauser and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Hans Petter Eikesdal

41 papers receiving 971 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hans Petter Eikesdal Norway 19 496 412 292 159 106 41 987
Soufiane Boumahdi United States 4 836 1.7× 560 1.4× 356 1.2× 72 0.5× 147 1.4× 4 1.2k
Nicolle Besselink Netherlands 17 672 1.4× 350 0.8× 440 1.5× 160 1.0× 109 1.0× 28 1.2k
JEFF EVANS United Kingdom 6 617 1.2× 397 1.0× 278 1.0× 50 0.3× 98 0.9× 24 1.2k
Marcus Bosenberg United States 13 801 1.6× 384 0.9× 322 1.1× 77 0.5× 123 1.2× 20 1.2k
Yongping Crawford United States 14 1.1k 2.2× 581 1.4× 450 1.5× 141 0.9× 133 1.3× 16 1.5k
James R. Whittle Australia 11 588 1.2× 357 0.9× 420 1.4× 71 0.4× 97 0.9× 39 1.0k
Victoria da Silva-Diz United States 9 691 1.4× 616 1.5× 345 1.2× 95 0.6× 87 0.8× 16 1.1k
Shaija Samuel United States 14 972 2.0× 739 1.8× 433 1.5× 101 0.6× 122 1.2× 16 1.5k
Steven A. Enkemann United States 18 783 1.6× 414 1.0× 246 0.8× 77 0.5× 121 1.1× 31 1.3k

Countries citing papers authored by Hans Petter Eikesdal

Since Specialization
Citations

This map shows the geographic impact of Hans Petter Eikesdal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Petter Eikesdal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Petter Eikesdal more than expected).

Fields of papers citing papers by Hans Petter Eikesdal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Petter Eikesdal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Petter Eikesdal. The network helps show where Hans Petter Eikesdal may publish in the future.

Co-authorship network of co-authors of Hans Petter Eikesdal

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Petter Eikesdal. A scholar is included among the top collaborators of Hans Petter Eikesdal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Petter Eikesdal. Hans Petter Eikesdal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nikolaienko, Oleksii, Hans Petter Eikesdal, Bjørnar Gilje, et al.. (2023). Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development. Genome Medicine. 15(1). 104–104. 13 indexed citations
2.
Ohnstad, Hege O., Elin Borgen, E. Mortensen, et al.. (2023). 103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1). ESMO Open. 8(1). 101327–101327. 1 indexed citations
3.
Deng, Wei, Jürgen Geisler, Stephanie Geisler, et al.. (2022). Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. Genome Medicine. 14(1). 86–86. 10 indexed citations
4.
Batalini, Felipe, D. Gulhan, Madeline Polak, et al.. (2022). Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clinical Cancer Research. 28(21). 4714–4723. 22 indexed citations
5.
Cao, Maria Dung, Thomas Fleischer, Morten Beck Rye, et al.. (2022). DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. Breast Cancer Research. 24(1). 43–43. 18 indexed citations
6.
Kellmann, Ralf, Kristin Viste, Hans Petter Eikesdal, et al.. (2020). An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range. Journal of the Endocrine Society. 4(6). bvaa047–bvaa047. 24 indexed citations
7.
Lønning, Per Eystein, Hans Petter Eikesdal, Inger Marie Løes, & Stian Knappskog. (2019). Constitutional Mosaic Epimutations – a hidden cause of cancer?. SHILAP Revista de lepidopterología. 3(4). 118–135. 20 indexed citations
8.
Eikesdal, Hans Petter, Lisa M. Becker, Yingqi Teng, et al.. (2018). BMP7 Signaling in TGFBR2 -Deficient Stromal Cells Provokes Epithelial Carcinogenesis. Molecular Cancer Research. 16(10). 1568–1578. 6 indexed citations
9.
Yndestad, Synnøve, et al.. (2017). Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer. Molecular Cancer Research. 16(1). 78–89. 26 indexed citations
10.
Yndestad, Synnøve, Stian Knappskog, Ranjan Chrisanthar, et al.. (2017). High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. Breast Cancer Research and Treatment. 163(1). 177–190. 18 indexed citations
11.
Kim, Jiha, Pedro Corrêa de Sampaio, Qian Peng, et al.. (2016). Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. JCI Insight. 1(21). e90733–e90733. 24 indexed citations
12.
Høberg‐Vetti, Hildegunn, Cathrine Bjorvatn, Bent Fiane, et al.. (2015). BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. European Journal of Human Genetics. 24(6). 881–888. 51 indexed citations
13.
Eikesdal, Hans Petter, Stian Knappskog, Turid Aas, & Per Eystein Lønning. (2014). TP53status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. Acta Oncologica. 53(10). 1347–1355. 12 indexed citations
14.
Johannessen, Tor‐Christian, Marek Wagner, Oddbjørn Straume, Rolf Bjerkvig, & Hans Petter Eikesdal. (2012). Tumor vasculature: the Achilles' heel of cancer?. Expert Opinion on Therapeutic Targets. 17(1). 7–20. 19 indexed citations
15.
Eikesdal, Hans Petter, et al.. (2002). Hyperthermia exhibits anti-vascular activity in the s.c. BT 4 An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat. International Journal of Hyperthermia. 18(2). 141–152. 14 indexed citations
16.
Eikesdal, Hans Petter, Willy Landuyt, & Olav Dahl. (2002). The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas. Cancer Letters. 178(2). 209–217. 14 indexed citations
17.
Eikesdal, Hans Petter, Rolf Bjerkvig, & Olav Dahl. (2001). Vinblastine and hyperthermia target the neovasculature in BT 4 AN rat gliomas: therapeutic implications of the vascular phenotype. International Journal of Radiation Oncology*Biology*Physics. 51(2). 535–544. 16 indexed citations
18.
Eikesdal, Hans Petter, et al.. (2001). Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors. Radiotherapy and Oncology. 60(2). 147–154. 30 indexed citations
19.
Eikesdal, Hans Petter, Rolf Bjerkvig, James A. Raleigh, Olav Mella, & Olav Dahl. (2001). Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiotherapy and Oncology. 61(3). 313–320. 20 indexed citations
20.
Eikesdal, Hans Petter, Baard‐Christian Schem, Olav Mella, & Olav Dahl. (2000). The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology*Biology*Physics. 46(3). 645–652. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Soufiane Boumahdi Breakdown of academic impact, for papers by Nicolle Besselink Breakdown of academic impact, for papers by JEFF EVANS Breakdown of academic impact, for papers by Marcus Bosenberg Breakdown of academic impact, for papers by Yongping Crawford Breakdown of academic impact, for papers by James R. Whittle Breakdown of academic impact, for papers by Victoria da Silva-Diz Breakdown of academic impact, for papers by Shaija Samuel Breakdown of academic impact, for papers by Steven A. Enkemann
Rankless by CCL
2026